Takeda Enlists Real World Evidence To Boost Marketed Entyvio

 
• By John Davis

Japan’s Takeda says it has confirmed the benefits of its best-selling inflammatory bowel disease therapy Entyvio in US medical practice through the collection of real world evidence.

Intestine
The Site of Intestinal Inflammation. Source: Shutterstock

More from Clinical Trials

More from R&D